4 results about "Polyethyleneglycol stearate" patented technology

The invention provides a grinding fluid, the grinding fluid comprises a base fluid, a grinding material, nano-diamond and a dispersion stabilizer, the base fluid comprises polyether and silicone oil, the grinding material comprises surface modified silicon carbide particles, and the dispersion stabilizer comprises polyethylene glycol stearate and polyvinylpyrrolidone. The surface roughness of a grinding piece can be reduced, the scratch density and microcracks of the surface are reduced, damage of grinding fluid to the grinding piece is reduced or even avoided, and the service life of a cutter can be prolonged. The invention also provides a preparation method of the grinding fluid and a process method using the grinding fluid.

This invention relates to a metal injection molding titanium alloy feedstock and its preparation method. By mass percentage, its components include: 60%-75% Ti-6Al-4V powder; 15%-20% binder; and 10%-20% pore-forming agent. The binder, by mass percentage, includes: 55%-60% polyethylene glycol, 22%-26% polyvinylpyrrolidone, 10%-13% polyethylene glycol stearate, and 3%-8% mannitol. The use of a specialized binder solves the problems of poor compatibility with binders, easy agglomeration of the feedstock, uneven dispersion of the pore-forming agent, and low pore connectivity during porous structure preparation.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a pharmaceutical composition containing Efiniprofen, a patch and a preparation method, the pharmaceutical composition containing Efiniprofen comprises the following components in parts by mass: 1.5-5.0 parts of Efiniprofen or pharmaceutically acceptable salts thereof, 1.0-5.0 parts of a penetration enhancer, and 0.1-10 parts of a stabilizer; the stabilizing agent is selected from one or more of octyl and decanoic acid coconut oil ester, isopropyl myristate, octyl and decanoic acid polyethylene glycol glyceride, polyethylene glycol-7 stearate and glyceryl monostearate and glyceryl distearate. According to the invention, the content reduction of the efiniprofen or the pharmaceutically acceptable salt during the stability period is effectively inhibited, and the stability is further improved, so that the pharmaceutical composition containing the efiniprofen can be stored for a long time; meanwhile, the in-vitro release effect of the pharmaceutical composition containing the iflurprofen is further improved.